Clinical trial · Observational
Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients
Diagnostic and Prognostic Role of New Inflammation Biomarkers in Patients With Malignant Pleural Mesothelioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational prospective analysis of biological characteristics of malignant mesothelioma (MM) patients. Frozen and paraffin-embedded tumor specimens and pleural effusion of patients will be collected and than will be analyzed with the following analyses: 1Purification of Tumour Associated Macrophages (TAM) and tumour cells from pleural effusions. 2.Mass spectrometry analysis of TAMs and tumor cells 3.Co focal microscopy analysis of macrophages, tumour cells and specimens derived from patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Mesothelioma | Malignant Mesothelioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- no treatment
- description
- no treatment
Primary outcomes (1)
- measure
- dissect the molecular mechanisms underlying the development of malignant mesothelioma
- timeFrame
- 24 months
- description
- characterization of the microenvironment (expression of M1 and M2 markers of polarized inflammation - cytokines and chemokines inducers or inhibitors of the inflammatory response) and the interplay between tumour cells and TAMs (expression of DNA damage markers) in order to dissect the molecular mechanisms underlying the development of malignant mesothelioma
Secondary outcomes (5)
- measure
- study of the effect of TAMs
- timeFrame
- 24 months
- description
- the study of the effect of TAMs on the induction of the DNA damage on (Human mast cell) HMC cells, and a possible synergic effect with asbestos fibers;
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Malignant pleural mesothelioma patients * Availability of plural effusion and frozen and paraffin-embedded tumor specimens. Exclusion Criteria: * Unavailability of plural effusion and frozen and paraffin-embedded tumor specimens.
References
Publications (0)
Data not yet available